Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
  • Research
    • Research
    • Publications
    • Global Research Centers
    • Case Development
    • Initiatives & Projects
    • Research Services
    • Seminars & Conferences
    →
  • Publications→

Publications

Publications

Filter Results: (991) Arrow Down
Filter Results: (991) Arrow Down Arrow Up

Show Results For

  • All HBS Web  (991)
    • People  (4)
    • News  (257)
    • Research  (614)
    • Events  (9)
    • Multimedia  (24)
  • Faculty Publications  (395)

Show Results For

  • All HBS Web  (991)
    • People  (4)
    • News  (257)
    • Research  (614)
    • Events  (9)
    • Multimedia  (24)
  • Faculty Publications  (395)
← Page 23 of 991 Results →
  • May 2023 (Revised June 2023)
  • Supplement

Novartis (B): Reimagining Medicine

By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,... View Details
Keywords: Health Care and Treatment; Business Model; Production; Business Strategy; Pharmaceutical Industry
Citation
Related
Casadesus-Masanell, Ramon, Claudio Feser, Karolin Frankenberger, and David Redaschi. "Novartis (B): Reimagining Medicine." Harvard Business School Supplement 723-444, May 2023. (Revised June 2023.)
  • May 2023 (Revised June 2023)
  • Case

Novartis (A): Reimagining Medicine

By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,... View Details
Keywords: Health Care and Treatment; Business Model; Leadership; Pharmaceutical Industry; Switzerland
Citation
Educators
Related
Casadesus-Masanell, Ramon, Claudio Feser, Karolin Frankenberger, and David Redaschi. "Novartis (A): Reimagining Medicine." Harvard Business School Case 723-443, May 2023. (Revised June 2023.)
  • September 2024
  • Case

Google Quantum AI

By: David B. Yoffie, Michael A. Cusumano and Matt Higgins
Quantum computing may be the most important nascent computing technology of the 21st century. It has the potential to impact industries ranging from drug discovery to cybersecurity. Google's Quantum AI is one of the leaders in quantum research. This case explores the... View Details
Keywords: Business Model; Price; Technological Innovation; Resource Allocation; Business Strategy; Information Technology Industry
Citation
Educators
Purchase
Related
Yoffie, David B., Michael A. Cusumano, and Matt Higgins. "Google Quantum AI." Harvard Business School Case 725-362, September 2024.

    Satish K. Tadikonda

    Satish Tadikonda is a Senior Lecturer in the Entrepreneurial Management Unit at Harvard Business School. In the MBA program, Satish teaches The Entrepreneurial Manager, a required first-year MBA course, and Entrepreneurship in Life Sciences, an elective course for... View Details

    • Article

    How to Avoid Executive Stress

    By: Thomas J. DeLong
    When teaching various groups of executives, the author relates the story of a man addicted to prescription drugs and his brother who is addicted to achievement. Each group relates to these two professionally successful men and sees that they live largely on the edge of... View Details
    Keywords: Behavior; Personal Development and Career; Personal Characteristics; Emotions
    Citation
    Related
    DeLong, Thomas J. "How to Avoid Executive Stress." Market Leader (Second Quarter 2012), 50–52.
    • July 2024
    • Case

    Gates Ventures: Making Alzheimer's a Forgotten Past

    By: Satish Tadikonda, William Marks, Shardule Shah and Calvin Marambo
    After a personal journey and interest in Alzheimer's Disease (AD) by Bill Gates, Gates Ventures set out to find the best way to accelerate innovation in the field of AD. In partnership with the Alzheimer's Drug Discovery Foundation, Gates Ventures created the... View Details
    Keywords: Philanthropy and Charitable Giving; Entrepreneurial Finance; Health Disorders; Mission and Purpose
    Citation
    Educators
    Purchase
    Related
    Tadikonda, Satish, William Marks, Shardule Shah, and Calvin Marambo. "Gates Ventures: Making Alzheimer's a Forgotten Past." Harvard Business School Case 824-075, July 2024.
    • 2022
    • Working Paper

    Regulatory Incentives for Innovation: The FDA's Breakthrough Therapy Designation

    By: Amitabh Chandra, Jennifer Kao, Kathleen Miller and Ariel D. Stern
    Regulators of new products confront a tradeoff between speeding a new product to market and collecting additional product quality information. The FDA’s Breakthrough Therapy Designation (BTD) provides an opportunity to understand if a regulator can use new policy to... View Details
    Keywords: Research and Development; Governing Rules, Regulations, and Reforms; Product Development
    Citation
    Find at Harvard
    Purchase
    Related
    Chandra, Amitabh, Jennifer Kao, Kathleen Miller, and Ariel D. Stern. "Regulatory Incentives for Innovation: The FDA's Breakthrough Therapy Designation." NBER Working Paper Series, No. 30712, December 2022.
    • September 2021
    • Article

    Trials and Terminations: Learning from Competitors' R&D Failures

    By: Joshua L. Krieger
    I analyze project continuation decisions where firms may resolve uncertainty through news about competitors' research and development (R&D) failures, as well as through their own results. I examine the trade-offs and interactions between product-market competition and... View Details
    Keywords: Research and Development; Projects; Failure; Decision Making; Learning
    Citation
    Find at Harvard
    Read Now
    Related
    Krieger, Joshua L. "Trials and Terminations: Learning from Competitors' R&D Failures." Management Science 67, no. 9 (September 2021).
    • 14 Nov 2017
    • First Look

    New Research and Ideas: November 14, 2017

    authors provide numerous examples of health care organizations that are taking these steps—and seeing impressive results. Publisher's link: https://www.hbs.edu/faculty/Pages/item.aspx?num=53460 forthcoming JAMA Cardiology The Central and Unacknowledged Role of the U.S.... View Details
    Keywords: Carmen Nobel
    • February 2019 (Revised July 2019)
    • Case

    Sales Force Management at Nobel Ilac

    By: Doug J. Chung and Gamze Yucaoglu
    Nobel Ilac was a Turkish generic pharmaceutical company marketing more than 100 drugs in 20 countries and, as of 2017, had over 2,500 employees worldwide. Nobel had implemented a transformation strategy—more specifically, a customer segmentation plan—whereby the sales... View Details
    Keywords: Sales Strategy; Compensation; Employee Retention; Recruiting; Pharmaceuticals; Salesforce Management; Strategy; Organizational Design; Human Resources; Compensation and Benefits; Employees; Retention; Recruitment; Pharmaceutical Industry; Turkey
    Citation
    Educators
    Purchase
    Related
    Chung, Doug J., and Gamze Yucaoglu. "Sales Force Management at Nobel Ilac." Harvard Business School Case 519-067, February 2019. (Revised July 2019.)
    • March 1992
    • Case

    Amgen, Inc.: Planning the Unplannable

    By: Nitin Nohria
    By the early 1990s, Amgen--a pharmaceutical company started little over a decade ago as Applied Molecular Genetics--was within range of becoming a billion-dollar company. With two extremely successful biotechnology drugs on the market, Amgen stood as the largest and... View Details
    Keywords: Growth and Development Strategy; Strategic Planning; Success; Risk and Uncertainty; Pharmaceutical Industry
    Citation
    Educators
    Purchase
    Related
    Nohria, Nitin. "Amgen, Inc.: Planning the Unplannable." Harvard Business School Case 492-052, March 1992.
    • August 2016
    • Simulation

    BDP Pharmaceuticals

    By: Kevin Schulman, Emma Rasiel and Suresh Balu
    Susan Durham has just been hired as the Chief Financial Officer of Blue Devil Pharmaceuticals (BDP). Her charge is to understand the optimal pathway for the development of a novel molecule, BDP-1, to understand the cost of drug development, the market opportunity, and... View Details
    Keywords: Finance; Entrepreneurship
    Citation
    Purchase
    Related
    Schulman, Kevin, Emma Rasiel, and Suresh Balu. "BDP Pharmaceuticals." Harvard Business School Simulation 317-702, August 2016.
    • July 2016
    • Case

    Blue D Pharmaceuticals

    By: Kevin Schulman, Emma Rasiel and Suresh Balu
    Susan Durham has just been hired as the Chief Financial Officer of Blue Devil Pharmaceuticals (BDP). Her charge is to understand the optimal pathway for the development of a novel molecule, BDP-1, to understand the cost of drug development, the market opportunity, and... View Details
    Keywords: Finance; Entrepreneurship
    Citation
    Educators
    Related
    Schulman, Kevin, Emma Rasiel, and Suresh Balu. "Blue D Pharmaceuticals." Harvard Business School Case 317-014, July 2016.
    • 26 Apr 2023
    • Cold Call Podcast

    How Martine Rothblatt Started a Company to Save Her Daughter

    Keywords: Re: Debora L. Spar; Pharmaceutical; Medical Devices & Supplies; Health
    • 2023
    • Working Paper

    The Political Economy of a 'Miracle Cure': The Case of Nebulized Ibuprofen and Its Diffusion in Argentina

    By: Sebastian Calónico, Rafael Di Tella and Juan Cruz Lopez Del Valle
    We document the diffusion of nebulized ibuprofen in Argentina as a treatment for COVID-19. As the pandemic spread, this clinically unsupported drug reached thousands of patients, even some seriously ill, despite warnings by the regulator and medical societies. Detailed... View Details
    Keywords: COVID-19; Health Care and Treatment; Health Pandemics; Adoption; Behavior; Governing Rules, Regulations, and Reforms; Learning
    Citation
    Find at Harvard
    Register to Read
    Related
    Calónico, Sebastian, Rafael Di Tella, and Juan Cruz Lopez Del Valle. "The Political Economy of a 'Miracle Cure': The Case of Nebulized Ibuprofen and Its Diffusion in Argentina." NBER Working Paper Series, No. 31781, October 2023.
    • September 2002 (Revised August 2003)
    • Case

    Genzyme's Gaucher Initiative: Global Risk and Responsibility

    By: Christopher A. Bartlett and Andrew N. McLean
    In Egypt, Genzyme's humanitarian commitment to treat all sufferers of the rare Gaucher disease worldwide first confronts its commercial imperative to recoup the huge investment required to bring the drug Cerezyme to market. Here Tomye Tierney must decide how to balance... View Details
    Keywords: Moral Sensibility; Investment; Emerging Markets; Negotiation; Corporate Social Responsibility and Impact; Business and Government Relations; Sales; Commercialization; Expansion; Value Creation
    Citation
    Educators
    Purchase
    Related
    Bartlett, Christopher A., and Andrew N. McLean. "Genzyme's Gaucher Initiative: Global Risk and Responsibility." Harvard Business School Case 303-048, September 2002. (Revised August 2003.)

      Managing Growth

      But marketing was important. Even if we produced the greatest drugs in the world, we’d be in trouble if we couldn’t get doctors to prescribe them or insurers to pay for them. As for our reluctance to look outside the company for ideas, I like to say that 0.1% of the... View Details
      • Web

      Overview | MBA

      uncertainties in affecting these opportunities. Develop approaches to ethical dilemmas bedeviling novel therapeutics, including investment in neglected diseases, the provision of life-saving drugs to disadvantaged patients and those in... View Details
      • Web

      Faculty & Advisors | MBA

      Underscore VC, she invested in fast growing B2B software startups, including life sciences tech products used by leading biopharma companies across the drug development cycle from R&D to commercial stages. She began her career at Michael... View Details
      • Web

      MS/MBA Biotechnology: Life Sciences | MBA

      new drug discoveries and therapeutics. The program is completed over two academic years, utilizing January terms and time in August at the start of the program. The curriculum emphasizes developing effective business models in the... View Details
      • ←
      • 23
      • 24
      • …
      • 49
      • 50
      • →
      ǁ
      Campus Map
      Harvard Business School
      Soldiers Field
      Boston, MA 02163
      →Map & Directions
      →More Contact Information
      • Make a Gift
      • Site Map
      • Jobs
      • Harvard University
      • Trademarks
      • Policies
      • Accessibility
      • Digital Accessibility
      Copyright © President & Fellows of Harvard College.